This article describes cell signaling network of metastatic prostate cancer(PCa)to bone and visceral organs in the context of tumor microenvironment and for the development of novel therapeutics.The article focuses on...This article describes cell signaling network of metastatic prostate cancer(PCa)to bone and visceral organs in the context of tumor microenvironment and for the development of novel therapeutics.The article focuses on our recent progress in the understanding of:1)The plasticity and dynamics of tumorestroma interaction;2)The significance of epigenetic reprogramming in conferring cancer growth,invasion and metastasis;3)New insights on altered junctional communication affecting PCa bone and brain metastases;4)Novel strategies to overcome therapeutic resistance to hormonal antagonists and chemotherapy;5)Geneticbased therapy to co-target tumor and bone stroma;6)PCa-bone-immune cell interaction and TBX2-WNTprotein signaling in bone metastasis;7)The roles of monoamine oxidase and reactive oxygen species in PCa growth and bone metastasis;and 8)Characterization of imprinting cluster of microRNA,in tumorestroma interaction.This article provides new approaches and insights of PCa metastases with emphasis on basic science and potential for clinical translation.This article referenced the details of the various approaches and discoveries described herein in peer-reviewed publications.We dedicate this article in our fond memory of Dr.Donald S.Coffey who taught us the spirit of sharing and the importance of focusing basic science discoveries toward translational medicine.展开更多
Recent cancer research has demonstrated the existence of circulating tumor cells(CTCs)in cancer patient’s blood.Once identified,CTC biomarkers will be invaluable tools for clinical diagnosis,prognosis and treatment.I...Recent cancer research has demonstrated the existence of circulating tumor cells(CTCs)in cancer patient’s blood.Once identified,CTC biomarkers will be invaluable tools for clinical diagnosis,prognosis and treatment.In this review,we propose ex vivo culture as a rational strategy for large scale amplification of the limited numbers of CTCs from a patient sample,to derive enough CTCs for accurate and reproducible characterization of the biophysical,biochemical,gene expressional and behavioral properties of the harvested cells.Because of tumor cell heterogeneity,it is important to amplify all the CTCs in a blood sample for a comprehensive understanding of their role in cancer metastasis.By analyzing critical steps and technical issues in ex vivo CTC culture,we developed a cost-effective and reproducible protocol directly culturing whole peripheral blood mononuclear cells,relying on an assumed survival advantage in CTCs and CTC-like cells over the normal cells to amplify this specified cluster of cancer cells.展开更多
One of the major challenges that clinicians face is in the difficulties of accurately monitoring disease progression.Prostate cancer is among these diseases and greatly affects the health of men globally.Circulating t...One of the major challenges that clinicians face is in the difficulties of accurately monitoring disease progression.Prostate cancer is among these diseases and greatly affects the health of men globally.Circulating tumor cells(CTCs)are a rare population of cancer cells that have shed from the primary tumor and entered the peripheral circulation.Not until recently,clinical applications of CTCs have been limited to using enumeration as a prognostic tool in Oncology.However,advances in emerging CTC technologies point toward new applications that could revolutionize the field of prostate cancer.It is now possible to study CTCs as components of a liquid biopsy based on morphological phenotypes,biochemical analyses,and genomic profiling.These advances allow us to gain insight into the heterogeneity and dynamics of cancer biology and to further study the mechanisms behind the evolution of therapeutic resistance.These recent developments utilizing CTCs for clinical applications will greatly impact the future of prostate cancer research and pave the way towards personalized care for men.展开更多
It is with the deepest sadness that we publish the following obituary for Donald S.Coffey,an Asian Journal of Urology(AJU)respected author.Dr.Coffey was invited to write a paper for the inaugural issue of AJU in 2014....It is with the deepest sadness that we publish the following obituary for Donald S.Coffey,an Asian Journal of Urology(AJU)respected author.Dr.Coffey was invited to write a paper for the inaugural issue of AJU in 2014.Despite he was 82 years old,he accepted our invitation and contributed a thoughtful perspective article.展开更多
From the early roots of modern urology to today,genitourinary(GU)cancers have been an important part of the fields of urology and cancer biology.As medical science has advanced,newer clinical and basic viewpoints have...From the early roots of modern urology to today,genitourinary(GU)cancers have been an important part of the fields of urology and cancer biology.As medical science has advanced,newer clinical and basic viewpoints have impacted the thinking and practice in this important field.As such,GU oncology has been consistently seen as an area of rapid evolution both in biological understanding and clinical care.GU cancers continue to rise in incidence worldwide.Moreover,they represent a significant portion of cancer mortality in Asia and the western world.These facts have been met with some of the boldest and most important advances in cancer biology and therapy that have reshaped this field.展开更多
We are delighted to publish the inaugural issue through which announces the launch of the Asian Journal of Urology(AJU).AJU is an international peer-reviewed journal jointly founded by the Chinese Urological Associati...We are delighted to publish the inaugural issue through which announces the launch of the Asian Journal of Urology(AJU).AJU is an international peer-reviewed journal jointly founded by the Chinese Urological Association(CUA)and the Second Military Medical University(SMMU)in Shanghai,China.The journal will publish articles in urologic specialties both scientifically and clinically.展开更多
基金The authors thank the financial support from NIH/National Cancer Institute grants(2P01CA098912)the editorial assistance from Gary Mawyer.
文摘This article describes cell signaling network of metastatic prostate cancer(PCa)to bone and visceral organs in the context of tumor microenvironment and for the development of novel therapeutics.The article focuses on our recent progress in the understanding of:1)The plasticity and dynamics of tumorestroma interaction;2)The significance of epigenetic reprogramming in conferring cancer growth,invasion and metastasis;3)New insights on altered junctional communication affecting PCa bone and brain metastases;4)Novel strategies to overcome therapeutic resistance to hormonal antagonists and chemotherapy;5)Geneticbased therapy to co-target tumor and bone stroma;6)PCa-bone-immune cell interaction and TBX2-WNTprotein signaling in bone metastasis;7)The roles of monoamine oxidase and reactive oxygen species in PCa growth and bone metastasis;and 8)Characterization of imprinting cluster of microRNA,in tumorestroma interaction.This article provides new approaches and insights of PCa metastases with emphasis on basic science and potential for clinical translation.This article referenced the details of the various approaches and discoveries described herein in peer-reviewed publications.We dedicate this article in our fond memory of Dr.Donald S.Coffey who taught us the spirit of sharing and the importance of focusing basic science discoveries toward translational medicine.
基金This work is supported by US NIH/NCI research grant(2PO1CA098912)edars-Sinai Medical Center Board of Governors Cancer Research Chair(LWKC),and US NIH/NCI(UO1CA198900)(HRT/EMP).
文摘Recent cancer research has demonstrated the existence of circulating tumor cells(CTCs)in cancer patient’s blood.Once identified,CTC biomarkers will be invaluable tools for clinical diagnosis,prognosis and treatment.In this review,we propose ex vivo culture as a rational strategy for large scale amplification of the limited numbers of CTCs from a patient sample,to derive enough CTCs for accurate and reproducible characterization of the biophysical,biochemical,gene expressional and behavioral properties of the harvested cells.Because of tumor cell heterogeneity,it is important to amplify all the CTCs in a blood sample for a comprehensive understanding of their role in cancer metastasis.By analyzing critical steps and technical issues in ex vivo CTC culture,we developed a cost-effective and reproducible protocol directly culturing whole peripheral blood mononuclear cells,relying on an assumed survival advantage in CTCs and CTC-like cells over the normal cells to amplify this specified cluster of cancer cells.
基金The authors would like to extend thanks to the following organizations and groups for their continued support of CTC research efforts at the Samuel Oschin Comprehensive Cancer Institute:St.Anthony Fund for Prostate Cancer Discover,CD McKinnon Memorial Fund for Aggressive Variant Prostate Cancers,Michael&Trisha Berns Family Fund for Discovery,Steven Spielberg Family Prostate Cancer Discovery Fund,Prostate Cancer Research Program of the US Department of Defense(W81XWH-11-1-0422)Prostate Cancer Foundation,Alliance for Nanotechnology in Cancer(1U01CA198900-01)the National Cancer Institute.
文摘One of the major challenges that clinicians face is in the difficulties of accurately monitoring disease progression.Prostate cancer is among these diseases and greatly affects the health of men globally.Circulating tumor cells(CTCs)are a rare population of cancer cells that have shed from the primary tumor and entered the peripheral circulation.Not until recently,clinical applications of CTCs have been limited to using enumeration as a prognostic tool in Oncology.However,advances in emerging CTC technologies point toward new applications that could revolutionize the field of prostate cancer.It is now possible to study CTCs as components of a liquid biopsy based on morphological phenotypes,biochemical analyses,and genomic profiling.These advances allow us to gain insight into the heterogeneity and dynamics of cancer biology and to further study the mechanisms behind the evolution of therapeutic resistance.These recent developments utilizing CTCs for clinical applications will greatly impact the future of prostate cancer research and pave the way towards personalized care for men.
文摘It is with the deepest sadness that we publish the following obituary for Donald S.Coffey,an Asian Journal of Urology(AJU)respected author.Dr.Coffey was invited to write a paper for the inaugural issue of AJU in 2014.Despite he was 82 years old,he accepted our invitation and contributed a thoughtful perspective article.
文摘From the early roots of modern urology to today,genitourinary(GU)cancers have been an important part of the fields of urology and cancer biology.As medical science has advanced,newer clinical and basic viewpoints have impacted the thinking and practice in this important field.As such,GU oncology has been consistently seen as an area of rapid evolution both in biological understanding and clinical care.GU cancers continue to rise in incidence worldwide.Moreover,they represent a significant portion of cancer mortality in Asia and the western world.These facts have been met with some of the boldest and most important advances in cancer biology and therapy that have reshaped this field.
文摘We are delighted to publish the inaugural issue through which announces the launch of the Asian Journal of Urology(AJU).AJU is an international peer-reviewed journal jointly founded by the Chinese Urological Association(CUA)and the Second Military Medical University(SMMU)in Shanghai,China.The journal will publish articles in urologic specialties both scientifically and clinically.
